Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting for Hodgkin's Disease

Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 34, pages 43–49 (2004)Cite this article

Summary:

We performed a retrospective study on recovery and survival of patients with T-cell NHL after autologous peripheral blood stem cell transplantation (APBSCT). Of a total of 39 patients with high-risk T-cell NHL, 33 were analyzed. Six patients who experienced early treatment mortality without full lymphocyte recovery were excluded. We chose absolute lymphocyte count (ALC) recovery as 1000 cells/μl as a cutoff value. ALC recovery day was defined as the first of 3 consecutive days with ALC above 1000 cells/μl. Univariate analysis revealed that age younger than 45 years, good international prognostic index, chemosensitive disease prior to APBSCT, and early ALC recovery (1000 cells/μl within 25 days of APBSCT) were predictors of prolonged survival. Multivariate analyses confirmed that chemosensitive disease prior to APBSCT and early ALC recovery were strongly associated with better overall survival (OS) (P=0.005 and 0.011, respectively) and progression-free survival (PFS) (P<0.001 and P=0.013, respectively). Our finding, that ALC recovery ⩾1000 cells/μl is an independent predictor of OS and PFS in T-cell NHL after APBSCT, suggests that earlier immune recovery may contribute to longer survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  3. Antman KH, Heitjan DF, Hortobagyi GN . High-dose chemotherapy for breast cancer. JAMA 1999; 282: 1701–1703.

    Article  CAS  PubMed  Google Scholar 

  4. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743–750.

    Article  CAS  PubMed  Google Scholar 

  5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  6. Porrata LF, Litzow MR, Tefferi A et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311–1318.

    Article  CAS  PubMed  Google Scholar 

  7. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    Article  CAS  PubMed  Google Scholar 

  8. Porrata LF, Ingle JN, Litzow MR et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001; 28: 865–871.

    Article  CAS  PubMed  Google Scholar 

  9. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.

    Article  CAS  PubMed  Google Scholar 

  10. Gordan LN, Sugrue MW, Lynch JW et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant 2003; 31: 1009–1013.

    Article  CAS  PubMed  Google Scholar 

  11. Heitger A, Neu N, Kern H et al. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood 1997; 90: 850–857.

    CAS  PubMed  Google Scholar 

  12. Schlenke P, Sheikhzadeh S, Weber K et al. Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 251–257.

    Article  CAS  PubMed  Google Scholar 

  13. Reimer P, Kunzmann V, Wilhelm M et al. Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol 2003; 82: 263–270.

    CAS  PubMed  Google Scholar 

  14. Fagnoni FF, Lozza L, Zibera C et al. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology 2002; 106: 27–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Douek DC, Vescio RA, Betts MR et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875–1881.

    Article  CAS  PubMed  Google Scholar 

  16. Guillaume T, Rubinstein DB, Symann M . Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471–1490.

    CAS  PubMed  Google Scholar 

  17. Damiani D, Stocchi R, Masolini P et al. Dendritic cell recovery after autologous stem cell transplantation. Bone Marrow Transplant 2002; 30: 261–266.

    Article  CAS  PubMed  Google Scholar 

  18. Akpek G, Lenz G, Lee SM et al. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant 2001; 28: 1105–1109.

    Article  CAS  PubMed  Google Scholar 

  19. Nagatoshi Y, Kawano Y, Watanabe T et al. Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population. Pediatr Transplant 2002; 6: 319–326.

    Article  PubMed  Google Scholar 

  20. Steingrimsdottir H, Gruber A, Bjorkholm M et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832–838.

    CAS  PubMed  Google Scholar 

  21. Tayebi H, Lapierre V, Saas P et al. Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. Br J Haematol 2001; 114: 698–700.

    Article  CAS  PubMed  Google Scholar 

  22. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.

    CAS  PubMed  Google Scholar 

  23. Pierelli L, Perillo A, Ferrandina G et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion 2001; 41: 1577–1585.

    Article  CAS  PubMed  Google Scholar 

  24. Baris D, Zahm SH . Epidemiology of lymphomas. Curr Opin Oncol 2000; 12: 383–394.

    Article  CAS  PubMed  Google Scholar 

  25. Ministry of Health and Welfare. Annual Report of the Korea Central Cancer Registry 2001 (Published in 2003).

  26. Ko YH, Kim CW, Park CS et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 806–812.

    CAS  Google Scholar 

  27. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    H Kim, H-J Sohn, S-E Kim, H-J Kang, S Park, S Kim, W-K Kim, J-S Lee & C Suh

Authors
  1. H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H-J Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S-E Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H-J Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Suh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, H., Sohn, HJ., Kim, SE. et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 34, 43–49 (2004). https://doi.org/10.1038/sj.bmt.1704530

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704530

Keywords

This article is cited by

Search

Advanced search

Quick links